icone plus
Contact
Abonnez-vous aux actualités
Reason for request
Renewal of inclusion
Clinical Benefit
Substantial
The actual benefit of DOTAREM remains substantial.
Clinical Added Value
minor
DOTAREM offers a minor improvement in actual benefit (level IV) in terms of safety over gadolinium-based contrast media presenting a high (OMNISCAN, MAGNEVIST) or moderate (MULTIHANCE) risk of nephrogenic systemic fibrosis according to the European Medicines Agency classification.
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
quqZ1CnjEwyKd0bx